Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 5 | 2023 | 87 | 2.990 |
Why?
|
| Hepatitis C | 4 | 2020 | 114 | 2.530 |
Why?
|
| Liver Function Tests | 8 | 2020 | 114 | 2.520 |
Why?
|
| Primary Health Care | 13 | 2023 | 703 | 2.270 |
Why?
|
| Liver Cirrhosis | 5 | 2023 | 301 | 2.090 |
Why?
|
| Referral and Consultation | 3 | 2020 | 383 | 1.550 |
Why?
|
| Liver Diseases | 4 | 2019 | 193 | 1.380 |
Why?
|
| Physicians, Primary Care | 2 | 2019 | 46 | 1.180 |
Why?
|
| Patient-Centered Care | 2 | 2018 | 106 | 1.090 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 334 | 1.090 |
Why?
|
| Transaminases | 2 | 2022 | 21 | 0.980 |
Why?
|
| Perception | 2 | 2021 | 189 | 0.860 |
Why?
|
| Hepatitis C Antibodies | 2 | 2019 | 19 | 0.840 |
Why?
|
| Financing, Personal | 1 | 2021 | 17 | 0.770 |
Why?
|
| Liver | 4 | 2021 | 1118 | 0.740 |
Why?
|
| Electronic Health Records | 3 | 2020 | 374 | 0.740 |
Why?
|
| Physicians | 2 | 2021 | 324 | 0.720 |
Why?
|
| Mitragyna | 1 | 2019 | 7 | 0.660 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 191 | 0.650 |
Why?
|
| Hepatitis C, Chronic | 1 | 2020 | 86 | 0.650 |
Why?
|
| Health Promotion | 1 | 2022 | 407 | 0.620 |
Why?
|
| Early Diagnosis | 1 | 2018 | 122 | 0.610 |
Why?
|
| Plant Extracts | 1 | 2019 | 122 | 0.600 |
Why?
|
| Humans | 32 | 2023 | 68618 | 0.590 |
Why?
|
| Retrospective Studies | 10 | 2023 | 7277 | 0.580 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 131 | 0.580 |
Why?
|
| Internal Medicine | 4 | 2020 | 118 | 0.570 |
Why?
|
| Clinical Competence | 2 | 2022 | 657 | 0.570 |
Why?
|
| Comprehensive Health Care | 1 | 2016 | 26 | 0.560 |
Why?
|
| Aspartate Aminotransferases | 3 | 2023 | 87 | 0.560 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.540 |
Why?
|
| Alanine Transaminase | 4 | 2021 | 137 | 0.530 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 163 | 0.530 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 46 | 0.500 |
Why?
|
| Adult | 16 | 2023 | 21403 | 0.490 |
Why?
|
| Internship and Residency | 4 | 2022 | 596 | 0.480 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 498 | 0.450 |
Why?
|
| Mass Screening | 1 | 2019 | 843 | 0.440 |
Why?
|
| Curriculum | 3 | 2022 | 575 | 0.430 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 232 | 0.420 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 1851 | 0.410 |
Why?
|
| Male | 17 | 2021 | 37321 | 0.400 |
Why?
|
| Chronic Disease | 1 | 2016 | 1330 | 0.390 |
Why?
|
| Fibrosis | 2 | 2023 | 371 | 0.370 |
Why?
|
| Middle Aged | 14 | 2021 | 21147 | 0.350 |
Why?
|
| Education, Medical, Graduate | 3 | 2022 | 214 | 0.340 |
Why?
|
| Biopsy | 2 | 2021 | 540 | 0.340 |
Why?
|
| Specialization | 2 | 2020 | 66 | 0.320 |
Why?
|
| Alkaline Phosphatase | 2 | 2018 | 71 | 0.310 |
Why?
|
| Workload | 2 | 2020 | 103 | 0.300 |
Why?
|
| Female | 14 | 2021 | 38074 | 0.300 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3259 | 0.250 |
Why?
|
| Cohort Studies | 2 | 2019 | 2358 | 0.210 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 11 | 0.190 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 123 | 0.190 |
Why?
|
| Risk Factors | 2 | 2022 | 5731 | 0.180 |
Why?
|
| Aged | 8 | 2021 | 14862 | 0.180 |
Why?
|
| United States | 5 | 2020 | 7367 | 0.180 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 2800 | 0.180 |
Why?
|
| Patient Participation | 1 | 2021 | 146 | 0.170 |
Why?
|
| Quality Improvement | 2 | 2020 | 413 | 0.170 |
Why?
|
| Health Expenditures | 2 | 2020 | 170 | 0.170 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 123 | 0.170 |
Why?
|
| Patient Transfer | 1 | 2020 | 86 | 0.160 |
Why?
|
| Pruritus | 1 | 2019 | 35 | 0.160 |
Why?
|
| Linear Models | 2 | 2020 | 521 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2019 | 93 | 0.160 |
Why?
|
| Health Care Costs | 2 | 2020 | 346 | 0.160 |
Why?
|
| Plants, Medicinal | 1 | 2019 | 43 | 0.160 |
Why?
|
| Patients | 1 | 2019 | 69 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2020 | 211 | 0.160 |
Why?
|
| Bilirubin | 1 | 2018 | 51 | 0.160 |
Why?
|
| Cost of Illness | 1 | 2020 | 206 | 0.150 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2017 | 3 | 0.150 |
Why?
|
| Fatigue | 1 | 2019 | 132 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 307 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 792 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 170 | 0.140 |
Why?
|
| Dyspnea | 1 | 2017 | 87 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 186 | 0.140 |
Why?
|
| Nephrologists | 1 | 2016 | 7 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2016 | 55 | 0.140 |
Why?
|
| Time Factors | 3 | 2020 | 4655 | 0.140 |
Why?
|
| Prevalence | 2 | 2018 | 1619 | 0.140 |
Why?
|
| Endocrinologists | 1 | 2016 | 12 | 0.140 |
Why?
|
| Rheumatologists | 1 | 2016 | 14 | 0.140 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 39 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 2279 | 0.140 |
Why?
|
| Risk Assessment | 1 | 2022 | 2007 | 0.130 |
Why?
|
| South Carolina | 2 | 2019 | 2752 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 438 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2017 | 344 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1465 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1046 | 0.120 |
Why?
|
| Risk Adjustment | 1 | 2015 | 49 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 281 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 807 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 161 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 772 | 0.120 |
Why?
|
| Hospitalization | 1 | 2020 | 978 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 442 | 0.110 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 711 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4848 | 0.110 |
Why?
|
| Hospitals | 1 | 2015 | 265 | 0.100 |
Why?
|
| Incidence | 1 | 2016 | 1603 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 1085 | 0.100 |
Why?
|
| Obesity | 1 | 2019 | 1076 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 694 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 756 | 0.090 |
Why?
|
| Hypertension | 1 | 2018 | 1535 | 0.080 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2020 | 64 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 1026 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2020 | 622 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7029 | 0.070 |
Why?
|
| Coronary Aneurysm | 1 | 2004 | 19 | 0.060 |
Why?
|
| Polytetrafluoroethylene | 1 | 2004 | 55 | 0.060 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2004 | 178 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2022 | 115 | 0.050 |
Why?
|
| Demography | 1 | 2021 | 279 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2022 | 453 | 0.040 |
Why?
|
| Efficiency | 1 | 2020 | 49 | 0.040 |
Why?
|
| Stents | 1 | 2004 | 657 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 106 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 130 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 241 | 0.040 |
Why?
|
| Documentation | 1 | 2019 | 83 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 201 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 121 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 1038 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 208 | 0.040 |
Why?
|
| Acute Disease | 1 | 2020 | 658 | 0.040 |
Why?
|
| Models, Economic | 1 | 2018 | 69 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2020 | 384 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 502 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 5717 | 0.040 |
Why?
|
| Prednisone | 1 | 2017 | 104 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2018 | 239 | 0.040 |
Why?
|
| Accreditation | 1 | 2017 | 72 | 0.040 |
Why?
|
| Health Services Research | 1 | 2018 | 209 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 780 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 8912 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2018 | 402 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 234 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 867 | 0.030 |
Why?
|
| Marital Status | 1 | 2015 | 65 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 378 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 274 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 320 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 219 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3705 | 0.030 |
Why?
|
| Infant | 1 | 2020 | 2891 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 3187 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 1426 | 0.020 |
Why?
|
| Child | 1 | 2020 | 6405 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2004 | 866 | 0.010 |
Why?
|